nodes	percent_of_prediction	percent_of_DWPC	metapath
Zuclopenthixol—DRD5—eyelid—melanoma	0.0584	0.492	CbGeAlD
Zuclopenthixol—HTR2A—hindlimb—melanoma	0.00762	0.0642	CbGeAlD
Zuclopenthixol—HTR2A—appendage—melanoma	0.00654	0.0551	CbGeAlD
Zuclopenthixol—HTR2A—endothelium—melanoma	0.00395	0.0333	CbGeAlD
Zuclopenthixol—HTR6—head—melanoma	0.00379	0.032	CbGeAlD
Zuclopenthixol—DRD5—head—melanoma	0.00369	0.0311	CbGeAlD
Zuclopenthixol—HTR2A—blood vessel—melanoma	0.00364	0.0307	CbGeAlD
Zuclopenthixol—DRD2—eye—melanoma	0.00294	0.0247	CbGeAlD
Zuclopenthixol—DRD2—retina—melanoma	0.00291	0.0245	CbGeAlD
Zuclopenthixol—DRD1—head—melanoma	0.00282	0.0238	CbGeAlD
Zuclopenthixol—HTR2A—neck—melanoma	0.0026	0.0219	CbGeAlD
Zuclopenthixol—HRH1—eye—melanoma	0.00232	0.0195	CbGeAlD
Zuclopenthixol—Hypotension—Vemurafenib—melanoma	0.00219	0.0045	CcSEcCtD
Zuclopenthixol—Neutropenia—Dactinomycin—melanoma	0.00218	0.00447	CcSEcCtD
Zuclopenthixol—Alanine aminotransferase increased—Temozolomide—melanoma	0.00215	0.00441	CcSEcCtD
Zuclopenthixol—Musculoskeletal discomfort—Vemurafenib—melanoma	0.00214	0.00439	CcSEcCtD
Zuclopenthixol—Pancytopenia—Carmustine—melanoma	0.00207	0.00425	CcSEcCtD
Zuclopenthixol—Sweating increased—Temozolomide—melanoma	0.00206	0.00421	CcSEcCtD
Zuclopenthixol—Neutropenia—Carmustine—melanoma	0.00204	0.00419	CcSEcCtD
Zuclopenthixol—Decreased appetite—Vemurafenib—melanoma	0.00204	0.00418	CcSEcCtD
Zuclopenthixol—Gastrointestinal disorder—Vemurafenib—melanoma	0.00203	0.00416	CcSEcCtD
Zuclopenthixol—Fatigue—Vemurafenib—melanoma	0.00202	0.00415	CcSEcCtD
Zuclopenthixol—Constipation—Vemurafenib—melanoma	0.00201	0.00412	CcSEcCtD
Zuclopenthixol—Pancytopenia—Temozolomide—melanoma	0.002	0.00411	CcSEcCtD
Zuclopenthixol—Neutropenia—Temozolomide—melanoma	0.00197	0.00405	CcSEcCtD
Zuclopenthixol—Dysuria—Temozolomide—melanoma	0.00197	0.00405	CcSEcCtD
Zuclopenthixol—Hyperglycaemia—Carmustine—melanoma	0.00197	0.00404	CcSEcCtD
Zuclopenthixol—Erectile dysfunction—Temozolomide—melanoma	0.00194	0.00398	CcSEcCtD
Zuclopenthixol—Agranulocytosis—Dactinomycin—melanoma	0.00194	0.00398	CcSEcCtD
Zuclopenthixol—HTR2A—eye—melanoma	0.00194	0.0163	CbGeAlD
Zuclopenthixol—Photosensitivity reaction—Temozolomide—melanoma	0.00193	0.00395	CcSEcCtD
Zuclopenthixol—Weight increased—Temozolomide—melanoma	0.00192	0.00394	CcSEcCtD
Zuclopenthixol—HTR2A—retina—melanoma	0.00192	0.0162	CbGeAlD
Zuclopenthixol—Weight decreased—Temozolomide—melanoma	0.00191	0.00391	CcSEcCtD
Zuclopenthixol—Hyperglycaemia—Temozolomide—melanoma	0.0019	0.0039	CcSEcCtD
Zuclopenthixol—Body temperature increased—Vemurafenib—melanoma	0.00186	0.00381	CcSEcCtD
Zuclopenthixol—HRH1—mammalian vulva—melanoma	0.00184	0.0155	CbGeAlD
Zuclopenthixol—ADRA2A—mammalian vulva—melanoma	0.00181	0.0152	CbGeAlD
Zuclopenthixol—Hepatobiliary disease—Temozolomide—melanoma	0.00178	0.00365	CcSEcCtD
Zuclopenthixol—Erythema—Bleomycin—melanoma	0.00174	0.00357	CcSEcCtD
Zuclopenthixol—Hot flush—Docetaxel—melanoma	0.00174	0.00356	CcSEcCtD
Zuclopenthixol—Hypersensitivity—Vemurafenib—melanoma	0.00173	0.00355	CcSEcCtD
Zuclopenthixol—Oedema peripheral—Carmustine—melanoma	0.00172	0.00353	CcSEcCtD
Zuclopenthixol—Menopausal symptoms—Docetaxel—melanoma	0.00172	0.00353	CcSEcCtD
Zuclopenthixol—Connective tissue disorder—Carmustine—melanoma	0.00172	0.00352	CcSEcCtD
Zuclopenthixol—ADRA1A—head—melanoma	0.0017	0.0143	CbGeAlD
Zuclopenthixol—Asthenia—Vemurafenib—melanoma	0.00168	0.00345	CcSEcCtD
Zuclopenthixol—Visual impairment—Carmustine—melanoma	0.00168	0.00345	CcSEcCtD
Zuclopenthixol—Urinary tract disorder—Temozolomide—melanoma	0.00167	0.00342	CcSEcCtD
Zuclopenthixol—DRD2—head—melanoma	0.00167	0.014	CbGeAlD
Zuclopenthixol—Oedema peripheral—Temozolomide—melanoma	0.00166	0.00341	CcSEcCtD
Zuclopenthixol—Pruritus—Vemurafenib—melanoma	0.00166	0.00341	CcSEcCtD
Zuclopenthixol—Connective tissue disorder—Temozolomide—melanoma	0.00166	0.0034	CcSEcCtD
Zuclopenthixol—Urethral disorder—Temozolomide—melanoma	0.00166	0.00339	CcSEcCtD
Zuclopenthixol—Eye disorder—Carmustine—melanoma	0.00163	0.00335	CcSEcCtD
Zuclopenthixol—Visual impairment—Temozolomide—melanoma	0.00163	0.00334	CcSEcCtD
Zuclopenthixol—Erythema—Dactinomycin—melanoma	0.00163	0.00333	CcSEcCtD
Zuclopenthixol—Ill-defined disorder—Bleomycin—melanoma	0.00162	0.00332	CcSEcCtD
Zuclopenthixol—Diarrhoea—Vemurafenib—melanoma	0.00161	0.00329	CcSEcCtD
Zuclopenthixol—Migraine—Docetaxel—melanoma	0.0016	0.00328	CcSEcCtD
Zuclopenthixol—Eye disorder—Temozolomide—melanoma	0.00158	0.00324	CcSEcCtD
Zuclopenthixol—Tinnitus—Temozolomide—melanoma	0.00158	0.00323	CcSEcCtD
Zuclopenthixol—Malaise—Bleomycin—melanoma	0.00157	0.00322	CcSEcCtD
Zuclopenthixol—Cardiac disorder—Temozolomide—melanoma	0.00157	0.00321	CcSEcCtD
Zuclopenthixol—Arrhythmia—Carmustine—melanoma	0.00156	0.0032	CcSEcCtD
Zuclopenthixol—Leukopenia—Bleomycin—melanoma	0.00156	0.0032	CcSEcCtD
Zuclopenthixol—Dizziness—Vemurafenib—melanoma	0.00155	0.00318	CcSEcCtD
Zuclopenthixol—Angiopathy—Temozolomide—melanoma	0.00153	0.00314	CcSEcCtD
Zuclopenthixol—Mental disorder—Carmustine—melanoma	0.00153	0.00314	CcSEcCtD
Zuclopenthixol—Ataxia—Docetaxel—melanoma	0.00153	0.00313	CcSEcCtD
Zuclopenthixol—Immune system disorder—Temozolomide—melanoma	0.00153	0.00313	CcSEcCtD
Zuclopenthixol—Malnutrition—Carmustine—melanoma	0.00152	0.00312	CcSEcCtD
Zuclopenthixol—Erythema—Carmustine—melanoma	0.00152	0.00312	CcSEcCtD
Zuclopenthixol—Ill-defined disorder—Dactinomycin—melanoma	0.00151	0.00309	CcSEcCtD
Zuclopenthixol—Liver function test abnormal—Docetaxel—melanoma	0.0015	0.00307	CcSEcCtD
Zuclopenthixol—Vomiting—Vemurafenib—melanoma	0.00149	0.00306	CcSEcCtD
Zuclopenthixol—Myalgia—Bleomycin—melanoma	0.00148	0.00304	CcSEcCtD
Zuclopenthixol—Rash—Vemurafenib—melanoma	0.00148	0.00304	CcSEcCtD
Zuclopenthixol—Mental disorder—Temozolomide—melanoma	0.00148	0.00303	CcSEcCtD
Zuclopenthixol—Dermatitis—Vemurafenib—melanoma	0.00148	0.00303	CcSEcCtD
Zuclopenthixol—Headache—Vemurafenib—melanoma	0.00147	0.00302	CcSEcCtD
Zuclopenthixol—Erythema—Temozolomide—melanoma	0.00147	0.00301	CcSEcCtD
Zuclopenthixol—Malnutrition—Temozolomide—melanoma	0.00147	0.00301	CcSEcCtD
Zuclopenthixol—Breast disorder—Docetaxel—melanoma	0.00147	0.00301	CcSEcCtD
Zuclopenthixol—Discomfort—Bleomycin—melanoma	0.00147	0.00301	CcSEcCtD
Zuclopenthixol—Malaise—Dactinomycin—melanoma	0.00147	0.00301	CcSEcCtD
Zuclopenthixol—Leukopenia—Dactinomycin—melanoma	0.00146	0.00298	CcSEcCtD
Zuclopenthixol—Nasopharyngitis—Docetaxel—melanoma	0.00145	0.00298	CcSEcCtD
Zuclopenthixol—Vision blurred—Carmustine—melanoma	0.00143	0.00294	CcSEcCtD
Zuclopenthixol—Alanine aminotransferase increased—Docetaxel—melanoma	0.00143	0.00294	CcSEcCtD
Zuclopenthixol—Tremor—Carmustine—melanoma	0.00143	0.00292	CcSEcCtD
Zuclopenthixol—Anaphylactic shock—Bleomycin—melanoma	0.00142	0.00292	CcSEcCtD
Zuclopenthixol—Agitation—Carmustine—melanoma	0.0014	0.00287	CcSEcCtD
Zuclopenthixol—Nausea—Vemurafenib—melanoma	0.00139	0.00286	CcSEcCtD
Zuclopenthixol—Thrombocytopenia—Bleomycin—melanoma	0.00139	0.00286	CcSEcCtD
Zuclopenthixol—Vision blurred—Temozolomide—melanoma	0.00139	0.00284	CcSEcCtD
Zuclopenthixol—Myalgia—Dactinomycin—melanoma	0.00138	0.00284	CcSEcCtD
Zuclopenthixol—Tremor—Temozolomide—melanoma	0.00138	0.00282	CcSEcCtD
Zuclopenthixol—Discomfort—Dactinomycin—melanoma	0.00137	0.0028	CcSEcCtD
Zuclopenthixol—Ill-defined disorder—Temozolomide—melanoma	0.00136	0.0028	CcSEcCtD
Zuclopenthixol—Leukopenia—Carmustine—melanoma	0.00136	0.00279	CcSEcCtD
Zuclopenthixol—Anorexia—Bleomycin—melanoma	0.00136	0.00278	CcSEcCtD
Zuclopenthixol—Agitation—Temozolomide—melanoma	0.00135	0.00277	CcSEcCtD
Zuclopenthixol—Pancytopenia—Docetaxel—melanoma	0.00133	0.00273	CcSEcCtD
Zuclopenthixol—Hypotension—Bleomycin—melanoma	0.00133	0.00273	CcSEcCtD
Zuclopenthixol—Malaise—Temozolomide—melanoma	0.00133	0.00272	CcSEcCtD
Zuclopenthixol—Vertigo—Temozolomide—melanoma	0.00132	0.00271	CcSEcCtD
Zuclopenthixol—Convulsion—Carmustine—melanoma	0.00132	0.0027	CcSEcCtD
Zuclopenthixol—Leukopenia—Temozolomide—melanoma	0.00132	0.0027	CcSEcCtD
Zuclopenthixol—HRH1—head—melanoma	0.00132	0.0111	CbGeAlD
Zuclopenthixol—Hypertension—Carmustine—melanoma	0.00131	0.00269	CcSEcCtD
Zuclopenthixol—Neutropenia—Docetaxel—melanoma	0.00131	0.00269	CcSEcCtD
Zuclopenthixol—Palpitations—Temozolomide—melanoma	0.0013	0.00266	CcSEcCtD
Zuclopenthixol—Thrombocytopenia—Dactinomycin—melanoma	0.0013	0.00266	CcSEcCtD
Zuclopenthixol—Musculoskeletal discomfort—Bleomycin—melanoma	0.0013	0.00266	CcSEcCtD
Zuclopenthixol—Myalgia—Carmustine—melanoma	0.0013	0.00266	CcSEcCtD
Zuclopenthixol—ADRA2A—head—melanoma	0.00129	0.0109	CbGeAlD
Zuclopenthixol—Anxiety—Carmustine—melanoma	0.00129	0.00265	CcSEcCtD
Zuclopenthixol—Paraesthesia—Bleomycin—melanoma	0.00128	0.00262	CcSEcCtD
Zuclopenthixol—Weight increased—Docetaxel—melanoma	0.00128	0.00262	CcSEcCtD
Zuclopenthixol—Convulsion—Temozolomide—melanoma	0.00127	0.00261	CcSEcCtD
Zuclopenthixol—Weight decreased—Docetaxel—melanoma	0.00127	0.0026	CcSEcCtD
Zuclopenthixol—Hypertension—Temozolomide—melanoma	0.00127	0.0026	CcSEcCtD
Zuclopenthixol—Dyspnoea—Bleomycin—melanoma	0.00127	0.0026	CcSEcCtD
Zuclopenthixol—Anorexia—Dactinomycin—melanoma	0.00126	0.00259	CcSEcCtD
Zuclopenthixol—Myalgia—Temozolomide—melanoma	0.00125	0.00257	CcSEcCtD
Zuclopenthixol—Anxiety—Temozolomide—melanoma	0.00125	0.00256	CcSEcCtD
Zuclopenthixol—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—melanoma	0.00124	0.00255	CcSEcCtD
Zuclopenthixol—Discomfort—Temozolomide—melanoma	0.00124	0.00254	CcSEcCtD
Zuclopenthixol—Decreased appetite—Bleomycin—melanoma	0.00124	0.00254	CcSEcCtD
Zuclopenthixol—Dry mouth—Temozolomide—melanoma	0.00122	0.00251	CcSEcCtD
Zuclopenthixol—Jaundice—Docetaxel—melanoma	0.00122	0.0025	CcSEcCtD
Zuclopenthixol—Pain—Bleomycin—melanoma	0.00122	0.00249	CcSEcCtD
Zuclopenthixol—Thrombocytopenia—Carmustine—melanoma	0.00122	0.00249	CcSEcCtD
Zuclopenthixol—Tachycardia—Carmustine—melanoma	0.00121	0.00248	CcSEcCtD
Zuclopenthixol—Musculoskeletal discomfort—Dactinomycin—melanoma	0.00121	0.00248	CcSEcCtD
Zuclopenthixol—Anaphylactic shock—Temozolomide—melanoma	0.0012	0.00246	CcSEcCtD
Zuclopenthixol—Anorexia—Carmustine—melanoma	0.00118	0.00243	CcSEcCtD
Zuclopenthixol—Hepatobiliary disease—Docetaxel—melanoma	0.00118	0.00243	CcSEcCtD
Zuclopenthixol—Nervous system disorder—Temozolomide—melanoma	0.00118	0.00241	CcSEcCtD
Zuclopenthixol—Thrombocytopenia—Temozolomide—melanoma	0.00118	0.00241	CcSEcCtD
Zuclopenthixol—Feeling abnormal—Bleomycin—melanoma	0.00117	0.0024	CcSEcCtD
Zuclopenthixol—Agranulocytosis—Docetaxel—melanoma	0.00117	0.00239	CcSEcCtD
Zuclopenthixol—Skin disorder—Temozolomide—melanoma	0.00117	0.00239	CcSEcCtD
Zuclopenthixol—Hypotension—Carmustine—melanoma	0.00116	0.00238	CcSEcCtD
Zuclopenthixol—Hyperhidrosis—Temozolomide—melanoma	0.00116	0.00238	CcSEcCtD
Zuclopenthixol—Decreased appetite—Dactinomycin—melanoma	0.00115	0.00236	CcSEcCtD
Zuclopenthixol—Fatigue—Dactinomycin—melanoma	0.00114	0.00235	CcSEcCtD
Zuclopenthixol—Anorexia—Temozolomide—melanoma	0.00114	0.00235	CcSEcCtD
Zuclopenthixol—Pain—Dactinomycin—melanoma	0.00113	0.00233	CcSEcCtD
Zuclopenthixol—Musculoskeletal discomfort—Carmustine—melanoma	0.00113	0.00232	CcSEcCtD
Zuclopenthixol—Body temperature increased—Bleomycin—melanoma	0.00112	0.00231	CcSEcCtD
Zuclopenthixol—Insomnia—Carmustine—melanoma	0.00112	0.0023	CcSEcCtD
Zuclopenthixol—Paraesthesia—Carmustine—melanoma	0.00112	0.00229	CcSEcCtD
Zuclopenthixol—Urinary tract disorder—Docetaxel—melanoma	0.00111	0.00227	CcSEcCtD
Zuclopenthixol—Dyspnoea—Carmustine—melanoma	0.00111	0.00227	CcSEcCtD
Zuclopenthixol—Oedema peripheral—Docetaxel—melanoma	0.00111	0.00227	CcSEcCtD
Zuclopenthixol—Somnolence—Carmustine—melanoma	0.0011	0.00226	CcSEcCtD
Zuclopenthixol—Connective tissue disorder—Docetaxel—melanoma	0.0011	0.00226	CcSEcCtD
Zuclopenthixol—Urethral disorder—Docetaxel—melanoma	0.0011	0.00226	CcSEcCtD
Zuclopenthixol—HTR2A—head—melanoma	0.0011	0.00926	CbGeAlD
Zuclopenthixol—Feeling abnormal—Dactinomycin—melanoma	0.00109	0.00224	CcSEcCtD
Zuclopenthixol—Musculoskeletal discomfort—Temozolomide—melanoma	0.00109	0.00224	CcSEcCtD
Zuclopenthixol—Insomnia—Temozolomide—melanoma	0.00109	0.00223	CcSEcCtD
Zuclopenthixol—Gastrointestinal pain—Dactinomycin—melanoma	0.00109	0.00222	CcSEcCtD
Zuclopenthixol—Visual impairment—Docetaxel—melanoma	0.00108	0.00222	CcSEcCtD
Zuclopenthixol—Decreased appetite—Carmustine—melanoma	0.00108	0.00221	CcSEcCtD
Zuclopenthixol—Paraesthesia—Temozolomide—melanoma	0.00108	0.00221	CcSEcCtD
Zuclopenthixol—Gastrointestinal disorder—Carmustine—melanoma	0.00107	0.0022	CcSEcCtD
Zuclopenthixol—Dyspnoea—Temozolomide—melanoma	0.00107	0.00219	CcSEcCtD
Zuclopenthixol—Somnolence—Temozolomide—melanoma	0.00107	0.00219	CcSEcCtD
Zuclopenthixol—Constipation—Carmustine—melanoma	0.00106	0.00218	CcSEcCtD
Zuclopenthixol—Pain—Carmustine—melanoma	0.00106	0.00218	CcSEcCtD
Zuclopenthixol—Dyspepsia—Temozolomide—melanoma	0.00106	0.00217	CcSEcCtD
Zuclopenthixol—Eye disorder—Docetaxel—melanoma	0.00105	0.00215	CcSEcCtD
Zuclopenthixol—Body temperature increased—Dactinomycin—melanoma	0.00105	0.00215	CcSEcCtD
Zuclopenthixol—Abdominal pain—Dactinomycin—melanoma	0.00105	0.00215	CcSEcCtD
Zuclopenthixol—Hypersensitivity—Bleomycin—melanoma	0.00105	0.00215	CcSEcCtD
Zuclopenthixol—Decreased appetite—Temozolomide—melanoma	0.00104	0.00214	CcSEcCtD
Zuclopenthixol—Cardiac disorder—Docetaxel—melanoma	0.00104	0.00214	CcSEcCtD
Zuclopenthixol—Gastrointestinal disorder—Temozolomide—melanoma	0.00104	0.00212	CcSEcCtD
Zuclopenthixol—Fatigue—Temozolomide—melanoma	0.00103	0.00212	CcSEcCtD
Zuclopenthixol—Constipation—Temozolomide—melanoma	0.00103	0.0021	CcSEcCtD
Zuclopenthixol—Pain—Temozolomide—melanoma	0.00103	0.0021	CcSEcCtD
Zuclopenthixol—Feeling abnormal—Carmustine—melanoma	0.00102	0.0021	CcSEcCtD
Zuclopenthixol—Asthenia—Bleomycin—melanoma	0.00102	0.00209	CcSEcCtD
Zuclopenthixol—Angiopathy—Docetaxel—melanoma	0.00102	0.00209	CcSEcCtD
Zuclopenthixol—Gastrointestinal pain—Carmustine—melanoma	0.00102	0.00208	CcSEcCtD
Zuclopenthixol—Immune system disorder—Docetaxel—melanoma	0.00101	0.00208	CcSEcCtD
Zuclopenthixol—Pruritus—Bleomycin—melanoma	0.00101	0.00206	CcSEcCtD
Zuclopenthixol—Arrhythmia—Docetaxel—melanoma	0.001	0.00206	CcSEcCtD
Zuclopenthixol—CYP2D6—head—melanoma	0.001	0.00844	CbGeAlD
Zuclopenthixol—Feeling abnormal—Temozolomide—melanoma	0.000989	0.00203	CcSEcCtD
Zuclopenthixol—Mental disorder—Docetaxel—melanoma	0.000984	0.00202	CcSEcCtD
Zuclopenthixol—Abdominal pain—Carmustine—melanoma	0.000982	0.00201	CcSEcCtD
Zuclopenthixol—Body temperature increased—Carmustine—melanoma	0.000982	0.00201	CcSEcCtD
Zuclopenthixol—Gastrointestinal pain—Temozolomide—melanoma	0.000981	0.00201	CcSEcCtD
Zuclopenthixol—Malnutrition—Docetaxel—melanoma	0.000978	0.002	CcSEcCtD
Zuclopenthixol—Erythema—Docetaxel—melanoma	0.000978	0.002	CcSEcCtD
Zuclopenthixol—Hypersensitivity—Dactinomycin—melanoma	0.000978	0.002	CcSEcCtD
Zuclopenthixol—Asthenia—Dactinomycin—melanoma	0.000952	0.00195	CcSEcCtD
Zuclopenthixol—Body temperature increased—Temozolomide—melanoma	0.000949	0.00194	CcSEcCtD
Zuclopenthixol—Abdominal pain—Temozolomide—melanoma	0.000949	0.00194	CcSEcCtD
Zuclopenthixol—HRH1—lymph node—melanoma	0.000922	0.00777	CbGeAlD
Zuclopenthixol—Hypersensitivity—Carmustine—melanoma	0.000915	0.00188	CcSEcCtD
Zuclopenthixol—Diarrhoea—Dactinomycin—melanoma	0.000908	0.00186	CcSEcCtD
Zuclopenthixol—ADRA2A—lymph node—melanoma	0.000905	0.00763	CbGeAlD
Zuclopenthixol—Vomiting—Bleomycin—melanoma	0.000905	0.00185	CcSEcCtD
Zuclopenthixol—Rash—Bleomycin—melanoma	0.000897	0.00184	CcSEcCtD
Zuclopenthixol—Dermatitis—Bleomycin—melanoma	0.000896	0.00184	CcSEcCtD
Zuclopenthixol—Asthenia—Carmustine—melanoma	0.000891	0.00183	CcSEcCtD
Zuclopenthixol—Hypersensitivity—Temozolomide—melanoma	0.000884	0.00181	CcSEcCtD
Zuclopenthixol—Syncope—Docetaxel—melanoma	0.000877	0.0018	CcSEcCtD
Zuclopenthixol—Leukopenia—Docetaxel—melanoma	0.000875	0.00179	CcSEcCtD
Zuclopenthixol—Palpitations—Docetaxel—melanoma	0.000864	0.00177	CcSEcCtD
Zuclopenthixol—Asthenia—Temozolomide—melanoma	0.000861	0.00177	CcSEcCtD
Zuclopenthixol—Loss of consciousness—Docetaxel—melanoma	0.00086	0.00176	CcSEcCtD
Zuclopenthixol—Diarrhoea—Carmustine—melanoma	0.00085	0.00174	CcSEcCtD
Zuclopenthixol—Pruritus—Temozolomide—melanoma	0.000849	0.00174	CcSEcCtD
Zuclopenthixol—Convulsion—Docetaxel—melanoma	0.000847	0.00174	CcSEcCtD
Zuclopenthixol—Nausea—Bleomycin—melanoma	0.000845	0.00173	CcSEcCtD
Zuclopenthixol—Hypertension—Docetaxel—melanoma	0.000844	0.00173	CcSEcCtD
Zuclopenthixol—Vomiting—Dactinomycin—melanoma	0.000844	0.00173	CcSEcCtD
Zuclopenthixol—Rash—Dactinomycin—melanoma	0.000837	0.00172	CcSEcCtD
Zuclopenthixol—Myalgia—Docetaxel—melanoma	0.000833	0.00171	CcSEcCtD
Zuclopenthixol—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—melanoma	0.000827	0.00169	CcSEcCtD
Zuclopenthixol—Dizziness—Carmustine—melanoma	0.000821	0.00168	CcSEcCtD
Zuclopenthixol—Diarrhoea—Temozolomide—melanoma	0.000821	0.00168	CcSEcCtD
Zuclopenthixol—Dry mouth—Docetaxel—melanoma	0.000814	0.00167	CcSEcCtD
Zuclopenthixol—Anaphylactic shock—Docetaxel—melanoma	0.000798	0.00164	CcSEcCtD
Zuclopenthixol—Dizziness—Temozolomide—melanoma	0.000794	0.00163	CcSEcCtD
Zuclopenthixol—Flupentixol—ABCB1—melanoma	0.000793	0.133	CrCbGaD
Zuclopenthixol—Vomiting—Carmustine—melanoma	0.00079	0.00162	CcSEcCtD
Zuclopenthixol—Nausea—Dactinomycin—melanoma	0.000788	0.00162	CcSEcCtD
Zuclopenthixol—Shock—Docetaxel—melanoma	0.000785	0.00161	CcSEcCtD
Zuclopenthixol—Rash—Carmustine—melanoma	0.000783	0.00161	CcSEcCtD
Zuclopenthixol—Nervous system disorder—Docetaxel—melanoma	0.000783	0.0016	CcSEcCtD
Zuclopenthixol—Dermatitis—Carmustine—melanoma	0.000782	0.0016	CcSEcCtD
Zuclopenthixol—Thrombocytopenia—Docetaxel—melanoma	0.000781	0.0016	CcSEcCtD
Zuclopenthixol—Tachycardia—Docetaxel—melanoma	0.000779	0.0016	CcSEcCtD
Zuclopenthixol—Headache—Carmustine—melanoma	0.000778	0.00159	CcSEcCtD
Zuclopenthixol—Skin disorder—Docetaxel—melanoma	0.000775	0.00159	CcSEcCtD
Zuclopenthixol—Clozapine—CYP1B1—melanoma	0.000771	0.129	CrCbGaD
Zuclopenthixol—Vomiting—Temozolomide—melanoma	0.000763	0.00156	CcSEcCtD
Zuclopenthixol—Anorexia—Docetaxel—melanoma	0.000761	0.00156	CcSEcCtD
Zuclopenthixol—Rash—Temozolomide—melanoma	0.000757	0.00155	CcSEcCtD
Zuclopenthixol—Dermatitis—Temozolomide—melanoma	0.000756	0.00155	CcSEcCtD
Zuclopenthixol—Headache—Temozolomide—melanoma	0.000752	0.00154	CcSEcCtD
Zuclopenthixol—Hypotension—Docetaxel—melanoma	0.000746	0.00153	CcSEcCtD
Zuclopenthixol—Nausea—Carmustine—melanoma	0.000738	0.00151	CcSEcCtD
Zuclopenthixol—Musculoskeletal discomfort—Docetaxel—melanoma	0.000727	0.00149	CcSEcCtD
Zuclopenthixol—Insomnia—Docetaxel—melanoma	0.000722	0.00148	CcSEcCtD
Zuclopenthixol—Paraesthesia—Docetaxel—melanoma	0.000717	0.00147	CcSEcCtD
Zuclopenthixol—Nausea—Temozolomide—melanoma	0.000713	0.00146	CcSEcCtD
Zuclopenthixol—Dyspnoea—Docetaxel—melanoma	0.000712	0.00146	CcSEcCtD
Zuclopenthixol—Somnolence—Docetaxel—melanoma	0.00071	0.00145	CcSEcCtD
Zuclopenthixol—Dyspepsia—Docetaxel—melanoma	0.000703	0.00144	CcSEcCtD
Zuclopenthixol—Decreased appetite—Docetaxel—melanoma	0.000694	0.00142	CcSEcCtD
Zuclopenthixol—Gastrointestinal disorder—Docetaxel—melanoma	0.000689	0.00141	CcSEcCtD
Zuclopenthixol—Fatigue—Docetaxel—melanoma	0.000688	0.00141	CcSEcCtD
Zuclopenthixol—Pain—Docetaxel—melanoma	0.000683	0.0014	CcSEcCtD
Zuclopenthixol—Constipation—Docetaxel—melanoma	0.000683	0.0014	CcSEcCtD
Zuclopenthixol—Feeling abnormal—Docetaxel—melanoma	0.000658	0.00135	CcSEcCtD
Zuclopenthixol—Gastrointestinal pain—Docetaxel—melanoma	0.000653	0.00134	CcSEcCtD
Zuclopenthixol—Abdominal pain—Docetaxel—melanoma	0.000631	0.00129	CcSEcCtD
Zuclopenthixol—Body temperature increased—Docetaxel—melanoma	0.000631	0.00129	CcSEcCtD
Zuclopenthixol—Hypersensitivity—Docetaxel—melanoma	0.000588	0.00121	CcSEcCtD
Zuclopenthixol—Asthenia—Docetaxel—melanoma	0.000573	0.00117	CcSEcCtD
Zuclopenthixol—Pruritus—Docetaxel—melanoma	0.000565	0.00116	CcSEcCtD
Zuclopenthixol—Diarrhoea—Docetaxel—melanoma	0.000546	0.00112	CcSEcCtD
Zuclopenthixol—Domperidone—ABCB1—melanoma	0.000533	0.0894	CrCbGaD
Zuclopenthixol—Dizziness—Docetaxel—melanoma	0.000528	0.00108	CcSEcCtD
Zuclopenthixol—Vomiting—Docetaxel—melanoma	0.000507	0.00104	CcSEcCtD
Zuclopenthixol—Rash—Docetaxel—melanoma	0.000503	0.00103	CcSEcCtD
Zuclopenthixol—Dermatitis—Docetaxel—melanoma	0.000503	0.00103	CcSEcCtD
Zuclopenthixol—Headache—Docetaxel—melanoma	0.0005	0.00102	CcSEcCtD
Zuclopenthixol—Nausea—Docetaxel—melanoma	0.000474	0.000972	CcSEcCtD
Zuclopenthixol—Nefazodone—ABCB1—melanoma	0.000443	0.0742	CrCbGaD
Zuclopenthixol—Trazodone—ABCB1—melanoma	0.00041	0.0687	CrCbGaD
Zuclopenthixol—Thioproperazine—ALB—melanoma	0.000409	0.0685	CrCbGaD
Zuclopenthixol—Pipotiazine—ALB—melanoma	0.000402	0.0674	CrCbGaD
Zuclopenthixol—Thiothixene—ALB—melanoma	0.000402	0.0674	CrCbGaD
Zuclopenthixol—Fluphenazine—ABCB1—melanoma	0.000332	0.0556	CrCbGaD
Zuclopenthixol—Chlorprothixene—ABCB1—melanoma	0.000302	0.0506	CrCbGaD
Zuclopenthixol—Trifluoperazine—ABCB1—melanoma	0.000265	0.0445	CrCbGaD
Zuclopenthixol—Quetiapine—ABCB1—melanoma	0.000257	0.0431	CrCbGaD
Zuclopenthixol—Clozapine—ABCB1—melanoma	0.000221	0.0371	CrCbGaD
Zuclopenthixol—Chlorpromazine—ALB—melanoma	0.000218	0.0366	CrCbGaD
Zuclopenthixol—Chlorpromazine—ABCB1—melanoma	0.000208	0.0349	CrCbGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—BRAF—melanoma	2.68e-05	6.92e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—IGF1—melanoma	2.67e-05	6.89e-05	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—TP53—melanoma	2.67e-05	6.89e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—CTNNB1—melanoma	2.67e-05	6.88e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—IGF1—melanoma	2.66e-05	6.87e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—CD80—melanoma	2.66e-05	6.85e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling by GPCR—MAPK1—melanoma	2.66e-05	6.85e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling by GPCR—EGFR—melanoma	2.66e-05	6.85e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—KIT—melanoma	2.65e-05	6.84e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—APC—melanoma	2.65e-05	6.84e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—PIK3CG—melanoma	2.65e-05	6.84e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—NRAS—melanoma	2.65e-05	6.84e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling by GPCR—MAPK1—melanoma	2.65e-05	6.84e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling by GPCR—EGFR—melanoma	2.65e-05	6.84e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—PRKCA—melanoma	2.64e-05	6.81e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—MAP2K1—melanoma	2.62e-05	6.76e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—EGF—melanoma	2.62e-05	6.76e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—ERCC2—melanoma	2.62e-05	6.75e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—IGF1—melanoma	2.61e-05	6.74e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—MMP9—melanoma	2.61e-05	6.74e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—PIK3CD—melanoma	2.6e-05	6.72e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—CDKN1A—melanoma	2.6e-05	6.72e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling by GPCR—MAPK1—melanoma	2.6e-05	6.71e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling by GPCR—EGFR—melanoma	2.6e-05	6.71e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—PTEN—melanoma	2.6e-05	6.7e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—NFKB1—melanoma	2.59e-05	6.67e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—GPCR downstream signaling—PIK3CA—melanoma	2.58e-05	6.66e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—MAP2K1—melanoma	2.58e-05	6.66e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—MAPK3—melanoma	2.58e-05	6.65e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—MAP2K1—melanoma	2.57e-05	6.64e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—PIK3CD—melanoma	2.56e-05	6.61e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—PIK3CD—melanoma	2.56e-05	6.6e-05	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—HRAS—melanoma	2.55e-05	6.59e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling by GPCR—KRAS—melanoma	2.55e-05	6.58e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—MAPK3—melanoma	2.54e-05	6.55e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—GPCR downstream signaling—PIK3CA—melanoma	2.54e-05	6.55e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling by GPCR—AKT1—melanoma	2.53e-05	6.54e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—GPCR downstream signaling—PIK3CA—melanoma	2.53e-05	6.53e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—MAP2K1—melanoma	2.53e-05	6.52e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—PIK3CD—melanoma	2.51e-05	6.47e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling by GPCR—KRAS—melanoma	2.51e-05	6.47e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—MYC—melanoma	2.51e-05	6.47e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling by GPCR—KRAS—melanoma	2.5e-05	6.46e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—FGF2—melanoma	2.49e-05	6.43e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—BRAF—melanoma	2.49e-05	6.43e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—GPCR downstream signaling—PIK3CA—melanoma	2.49e-05	6.41e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling by GPCR—KRAS—melanoma	2.46e-05	6.34e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—MAPK1—melanoma	2.45e-05	6.33e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—FGF2—melanoma	2.45e-05	6.33e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—EGFR—melanoma	2.45e-05	6.33e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—FGF2—melanoma	2.45e-05	6.32e-05	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—IL6—melanoma	2.44e-05	6.3e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—PIK3CB—melanoma	2.43e-05	6.27e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—IGF1—melanoma	2.43e-05	6.27e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—MAPK1—melanoma	2.42e-05	6.24e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—EGFR—melanoma	2.42e-05	6.23e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—PTGS2—melanoma	2.41e-05	6.21e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—FGF2—melanoma	2.4e-05	6.2e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—MAP2K1—melanoma	2.35e-05	6.06e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—VEGFA—melanoma	2.35e-05	6.05e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling by GPCR—PIK3CA—melanoma	2.34e-05	6.04e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—MDM2—melanoma	2.33e-05	6.02e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—PIK3CD—melanoma	2.33e-05	6.02e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—STAT3—melanoma	2.32e-05	6e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—NRAS—melanoma	2.32e-05	5.98e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—KRAS—melanoma	2.32e-05	5.98e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—GPCR downstream signaling—PIK3CA—melanoma	2.31e-05	5.96e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling by GPCR—PIK3CA—melanoma	2.3e-05	5.95e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—ERBB2—melanoma	2.3e-05	5.94e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling by GPCR—PIK3CA—melanoma	2.3e-05	5.93e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—MDM2—melanoma	2.3e-05	5.92e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—MDM2—melanoma	2.29e-05	5.91e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—KRAS—melanoma	2.28e-05	5.89e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—PIK3CB—melanoma	2.27e-05	5.86e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—ERBB2—melanoma	2.26e-05	5.84e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—ERBB2—melanoma	2.26e-05	5.83e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling by GPCR—PIK3CA—melanoma	2.26e-05	5.82e-05	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—AKT1—melanoma	2.25e-05	5.81e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—MDM2—melanoma	2.25e-05	5.8e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—PIK3CB—melanoma	2.23e-05	5.76e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—FGF2—melanoma	2.23e-05	5.76e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—PIK3CB—melanoma	2.23e-05	5.75e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—MAPK3—melanoma	2.22e-05	5.73e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—ERBB2—melanoma	2.22e-05	5.72e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—PIK3CB—melanoma	2.19e-05	5.64e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—CXCL8—melanoma	2.18e-05	5.63e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling by GPCR—HRAS—melanoma	2.17e-05	5.59e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—MYC—melanoma	2.16e-05	5.57e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—CXCL8—melanoma	2.15e-05	5.54e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—CXCL8—melanoma	2.14e-05	5.53e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling by GPCR—HRAS—melanoma	2.13e-05	5.5e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—CDKN1B—melanoma	2.13e-05	5.5e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—PIK3CA—melanoma	2.13e-05	5.49e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling by GPCR—HRAS—melanoma	2.13e-05	5.49e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—MAPK1—melanoma	2.11e-05	5.45e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—EGFR—melanoma	2.11e-05	5.45e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—GPCR downstream signaling—AKT1—melanoma	2.11e-05	5.44e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—CXCL8—melanoma	2.1e-05	5.42e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—PTEN—melanoma	2.1e-05	5.42e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—PIK3CA—melanoma	2.1e-05	5.41e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—CDKN1B—melanoma	2.1e-05	5.41e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—CDKN1B—melanoma	2.09e-05	5.4e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—MDM2—melanoma	2.09e-05	5.39e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling by GPCR—HRAS—melanoma	2.09e-05	5.39e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—CASP3—melanoma	2.09e-05	5.39e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—IL2—melanoma	2.08e-05	5.38e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling by GPCR—IL6—melanoma	2.07e-05	5.35e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—GPCR downstream signaling—AKT1—melanoma	2.07e-05	5.35e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—GPCR downstream signaling—AKT1—melanoma	2.07e-05	5.34e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—PIK3CG—melanoma	2.07e-05	5.33e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—TP53—melanoma	2.06e-05	5.31e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—ERBB2—melanoma	2.06e-05	5.31e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—CASP3—melanoma	2.05e-05	5.3e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—CDKN1B—melanoma	2.05e-05	5.3e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—IL2—melanoma	2.05e-05	5.29e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—CASP3—melanoma	2.05e-05	5.29e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—IL2—melanoma	2.05e-05	5.28e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling by GPCR—IL6—melanoma	2.04e-05	5.27e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling by GPCR—IL6—melanoma	2.04e-05	5.25e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—CCND1—melanoma	2.03e-05	5.24e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—PIK3CB—melanoma	2.03e-05	5.24e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—GPCR downstream signaling—AKT1—melanoma	2.03e-05	5.24e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—CTNNB1—melanoma	2.01e-05	5.19e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—CASP3—melanoma	2.01e-05	5.19e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—IL2—melanoma	2.01e-05	5.18e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—CCND1—melanoma	2e-05	5.16e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling by GPCR—IL6—melanoma	2e-05	5.16e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—CCND1—melanoma	2e-05	5.15e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—KRAS—melanoma	1.99e-05	5.15e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—PPARG—melanoma	1.99e-05	5.15e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—CTNNB1—melanoma	1.98e-05	5.11e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—CTNNB1—melanoma	1.98e-05	5.1e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—MMP9—melanoma	1.97e-05	5.09e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—HRAS—melanoma	1.97e-05	5.08e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—CDKN1A—melanoma	1.97e-05	5.07e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—PTEN—melanoma	1.96e-05	5.06e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—CCND1—melanoma	1.96e-05	5.05e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—CXCL8—melanoma	1.95e-05	5.04e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—NFKB1—melanoma	1.95e-05	5.04e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—MMP9—melanoma	1.94e-05	5.01e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—HRAS—melanoma	1.94e-05	5.01e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—CTNNB1—melanoma	1.94e-05	5e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—MMP9—melanoma	1.94e-05	5e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—CDKN1A—melanoma	1.93e-05	4.99e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—CDKN1A—melanoma	1.93e-05	4.98e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—PTEN—melanoma	1.93e-05	4.98e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—PTEN—melanoma	1.93e-05	4.97e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—NFKB1—melanoma	1.92e-05	4.96e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—NFKB1—melanoma	1.92e-05	4.95e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling by GPCR—AKT1—melanoma	1.91e-05	4.94e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—CDKN1B—melanoma	1.91e-05	4.92e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—MMP9—melanoma	1.9e-05	4.9e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—CDKN1A—melanoma	1.89e-05	4.89e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—PTEN—melanoma	1.89e-05	4.88e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—GPCR downstream signaling—AKT1—melanoma	1.89e-05	4.87e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—IL6—melanoma	1.89e-05	4.86e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling by GPCR—AKT1—melanoma	1.88e-05	4.86e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—NFKB1—melanoma	1.88e-05	4.85e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling by GPCR—AKT1—melanoma	1.88e-05	4.85e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—CASP3—melanoma	1.87e-05	4.82e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—IL2—melanoma	1.87e-05	4.82e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—IL6—melanoma	1.86e-05	4.79e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling by GPCR—AKT1—melanoma	1.84e-05	4.76e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—PIK3CA—melanoma	1.83e-05	4.73e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—CCND1—melanoma	1.82e-05	4.69e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—PIK3CD—melanoma	1.82e-05	4.69e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—CTNNB1—melanoma	1.8e-05	4.65e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—ALB—melanoma	1.79e-05	4.63e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—TP53—melanoma	1.77e-05	4.57e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—VEGFA—melanoma	1.77e-05	4.57e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—MMP9—melanoma	1.77e-05	4.56e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—CDKN1A—melanoma	1.76e-05	4.54e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—PTEN—melanoma	1.76e-05	4.53e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—STAT3—melanoma	1.75e-05	4.53e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—NRAS—melanoma	1.75e-05	4.52e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—NFKB1—melanoma	1.75e-05	4.51e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—VEGFA—melanoma	1.74e-05	4.5e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—VEGFA—melanoma	1.74e-05	4.49e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—AKT1—melanoma	1.74e-05	4.49e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—STAT3—melanoma	1.73e-05	4.45e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—STAT3—melanoma	1.72e-05	4.44e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—NRAS—melanoma	1.72e-05	4.44e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—NRAS—melanoma	1.72e-05	4.43e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—AKT1—melanoma	1.71e-05	4.42e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—VEGFA—melanoma	1.71e-05	4.4e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—HRAS—melanoma	1.7e-05	4.38e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—STAT3—melanoma	1.69e-05	4.36e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—NRAS—melanoma	1.69e-05	4.35e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—MAPK3—melanoma	1.68e-05	4.32e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—MAPK3—melanoma	1.65e-05	4.26e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—MAPK3—melanoma	1.65e-05	4.25e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—MYC—melanoma	1.63e-05	4.21e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—IL6—melanoma	1.62e-05	4.19e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—MAPK3—melanoma	1.61e-05	4.17e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—MYC—melanoma	1.6e-05	4.14e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—MYC—melanoma	1.6e-05	4.13e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—MAPK1—melanoma	1.59e-05	4.11e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—EGFR—melanoma	1.59e-05	4.11e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—VEGFA—melanoma	1.59e-05	4.09e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—PIK3CB—melanoma	1.58e-05	4.09e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—MYC—melanoma	1.57e-05	4.05e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—STAT3—melanoma	1.57e-05	4.05e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—MAPK1—melanoma	1.57e-05	4.05e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—PTGS2—melanoma	1.57e-05	4.05e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—EGFR—melanoma	1.57e-05	4.05e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—NRAS—melanoma	1.57e-05	4.04e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—MAPK1—melanoma	1.57e-05	4.04e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—EGFR—melanoma	1.57e-05	4.04e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—MAPK1—melanoma	1.54e-05	3.96e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—EGFR—melanoma	1.54e-05	3.96e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—KRAS—melanoma	1.51e-05	3.89e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—MAPK3—melanoma	1.5e-05	3.87e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—AKT1—melanoma	1.5e-05	3.86e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—KRAS—melanoma	1.48e-05	3.82e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—PIK3CA—melanoma	1.48e-05	3.82e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—KRAS—melanoma	1.48e-05	3.82e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—MYC—melanoma	1.46e-05	3.77e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—KRAS—melanoma	1.45e-05	3.74e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—MAPK1—melanoma	1.43e-05	3.68e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—EGFR—melanoma	1.43e-05	3.68e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—PIK3CA—melanoma	1.38e-05	3.57e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—PTEN—melanoma	1.37e-05	3.53e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—PIK3CA—melanoma	1.36e-05	3.51e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—PIK3CA—melanoma	1.36e-05	3.51e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—KRAS—melanoma	1.35e-05	3.48e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—TP53—melanoma	1.34e-05	3.45e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—PIK3CA—melanoma	1.33e-05	3.44e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—TP53—melanoma	1.32e-05	3.4e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—TP53—melanoma	1.31e-05	3.39e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—TP53—melanoma	1.29e-05	3.33e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—HRAS—melanoma	1.28e-05	3.3e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—HRAS—melanoma	1.26e-05	3.25e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—HRAS—melanoma	1.26e-05	3.24e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—PIK3CA—melanoma	1.24e-05	3.2e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—HRAS—melanoma	1.23e-05	3.18e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—IL6—melanoma	1.23e-05	3.16e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—AKT1—melanoma	1.21e-05	3.12e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—IL6—melanoma	1.21e-05	3.11e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—IL6—melanoma	1.2e-05	3.1e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—TP53—melanoma	1.2e-05	3.09e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—IL6—melanoma	1.18e-05	3.05e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—HRAS—melanoma	1.15e-05	2.96e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—AKT1—melanoma	1.13e-05	2.92e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—AKT1—melanoma	1.11e-05	2.87e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—AKT1—melanoma	1.11e-05	2.86e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—IL6—melanoma	1.1e-05	2.83e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—AKT1—melanoma	1.09e-05	2.81e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—AKT1—melanoma	1.01e-05	2.61e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—PIK3CA—melanoma	9.65e-06	2.49e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—AKT1—melanoma	7.89e-06	2.03e-05	CbGpPWpGaD
